You are here: Industry Insights > BMS

News List

BMS can breathe easier now: Celgene’s Revlimid has escaped a big patent challenge fiercepharma
February 24, 2019
When Bristol-Myers Squibb picked up Celgene in one of biopharma’s biggest deals ever last month, investors tagged one big risk: Celgene’s megablockbuster Revlimid faced patent challenges that could take a big bite out of sales.
Opdivo Plus Yervoy Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer americanpharmaceuticalreview
February 18, 2019
Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC)....
Merck/Pfizer up the pressure on BMS in first-line kidney cancer pharmaphorum
February 14, 2019
The FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney cancer, setting up a possible approval in June and piling more pressure on Bristol-Myers Squibb.
BMS talks up Celgene merger to divert Opdivo disappointment fiercepharma
January 28, 2019
In the wake of bad news from its closely watched immuno-oncology portfolio, Bristol-Myers Squibb executives did their best Thursday to talk up the six near-term product launches they’re expecting from the company's $74 billion merger with Celgene. But the
BMS talks up Celgene merger to divert Opdivo disappointment fiercepharma
January 28, 2019
In the wake of bad news from its closely watched immuno-oncology portfolio, Bristol-Myers Squibb executives did their best Thursday to talk up the six near-term product launches they’re expecting from the company's $74 billion merger with Celgene. But the
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma worldpharmanews
January 17, 2019
This decision represents the first approval of an Immuno-Oncology (I-O) combination therapy for patients with this type of cancer in the European Union.
BMS gets new OK for Opdivo/Yervoy in kidney cancer pharmaphorum
January 17, 2019
Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal cell carcinoma (RCC), the most common form of kidney cancer.
BMS acquires Celgene for an equity value of $74bn pharmaceutical-technology
January 04, 2019
Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement to acquire Celgene via a cash and stock transaction with an equity value of $74bn; Celgene shares have been valued at $102.43 per share.
BMS acquires Celgene for an equity value of $74bn pharmaceutical-technology
January 04, 2019
Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement to acquire Celgene via a cash and stock transaction with an equity value of $74bn; Celgene shares have been valued at $102.43 per share....
BMS receives offer from Taisho to purchase UPSA cphi-online
January 02, 2019
The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page